Related Experiment Video
Updated: Jul 19, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Sustained release octreotide may have a role in the treatment of malignant bowel obstruction
Cristian Massacesi1, Giordano Galeazzi
1Department of Oncology and Radiotherapy, Ospedali Riuniti Ancona, Ancona Istituto Oncologico Marche (IOM) for Palliative Care, Ancona, Italy. cristian.massacesi@libero.it
Abstract:
Daily or continuous infusion octreotide is effective in relieving the gastrointestinal symptoms associated with inoperable malignant bowel obstruction (MBO). The sustained release (LAR) formulation of octreotide provides sustained exposure of the drug. This preliminary study aimed to investigate the efficacy of octreotide LAR (20 mg) for reducing gastrointestinal symptoms or nasogastric tube (NGT) secretions in patients with MBO. In patients with NGT (n = 8), octreotide LAR reduced NGT secretions from day one onwards, and NGT was removed in one patient. In patients without NGT (n = 4), octreotide LAR reduced episodes of vomiting and the severity of nausea, and this reduction was maintained throughout the study. Tolerability was good. In conclusion, the more convenient dosing schedule and potential activity of octreotide LAR may have a role in controlling MBO symptoms, and, therefore, it deserves further studies.
Related Concept Videos
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Intestinal Obstruction II: Pathophysiology
Drugs for Treatment of Constipation-Predominant IBS
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists